Project Grant R44HL104885

This $500,000 Project Grant award from the U.S. Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program supports research to improve understanding of delayed diagnosis of venous thromboembolism (VTE) in ambulatory care settings. The project aims to leverage electronic health record (EHR) data and stakeholder expertise to identify risk factors, disparities, and outcomes associated with delayed and missed VTE diagnosis in...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant of $275,000 awarded to Xtract Medical Inc. aims to develop and demonstrate the feasibility of a novel catheter-based system for improved removal of blood clots during mechanical thrombectomy procedures to treat venous thromboembolism (VTE). The proposed system is designed to effectively remove large blood clots while minimizing damage to blood vessels and reducing complications such as...

Federal Cooperative Agreement Summary STAT-CAT Clinical Trial Award Brigham & Women's Hospital, Inc. received a $4.58 million Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) randomized clinical trial. Awarded on August 1, 2025, with performance through July 31, 2026, this initiative will enroll up to 4,000...

Federal Project Grant Award Summary Emory University received a $1.59M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded May 1, 2025, with completion targeted for January 31, 2029. The project delivers development and validation of an innovative diagnostic technology platform for detecting heparin-induced thrombocytopenia (HIT), a serious adverse drug reaction affecting 0.1%-5.0% of patients...

Federal Grant Award Summary Baylor College of Medicine received a $721,826 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 22, 2025, through May 31, 2030. The project develops a multi-modal dynamic risk prediction model for venous thromboembolism (VTE) and cancer-related bleeding (CRB) in approximately 330,000 cancer patients across three geographically and demographically diverse U.S....

Federal Cooperative Agreement Summary Brigham & Women's Hospital Inc. received a $1.72 million Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for July 31, 2032. This award funds the STAT-CAT (Statins to Prevent Cancer Associated Venous Thromboembolism) trial, a randomized clinical study designed to evaluate whether rosuvastatin 20 mg daily can...

The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a $186,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 16, 2025, through August 31, 2030. This grant supports a systematic analysis of venous thromboembolism (VTE) data derived from a multicenter prospective cohort study of pediatric VTE patients. The research addresses a critical knowledge gap regarding the factors contributing to VTE...

Grant Award Summary Vena Vitals Inc., a women-owned small business, received a $920,616 Project Grant award dated September 24, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports development and validation of VeriSleep, a wearable device designed to provide continuous, non-invasive blood pressure (BP) monitoring during sleep through beat-to-beat sensing technology. The device quantifies...

This $1,199,991 Project Grant award from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program aims to develop novel technologies for real-time assessment of blood clot properties to improve stroke treatment. The key products and services under this grant include: Integration of a sub-millimeter Raman fiber probe into a catheter for intravascular, in-vivo measurement of clot chemical composition. Training of a convolutional neural network to...

Federal Grant Award Summary Award Overview: The National Heart, Lung, and Blood Institute (NHLBI) awarded Actiox LLC a $699,468 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for development and validation of a wearable microneedle-based biosensor for continuous cardiac troponin I (cTnI) monitoring. The award was obligated on September 10, 2025, with a completion date of October 31, 2026, and will be performed at the company's La Jolla, California facility....